Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)

NCT04423731 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

251

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Pancreatic Adenocarcinoma
Chemotherapy Effect
Borderline Resectable Pancreatic Adenocarcinoma
Pancreatectomy

Interventions

DRUG: Folfirinox

Sponsor

Oslo University Hospital